SEC Form 4 · accession 0000899243-17-006602
CTI BIOPHARMA CORP · CTIC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Bruce J. Seeley
Officer — EVP, Chief Commercial Officer
Period of report
Mar 1, 2017
Accepted (ET)
Mar 6, 2017 · 5:01 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000891293
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $4.33 | Mar 1, 2017 | A | 60,000 | A | — | Feb 28, 2027 | Common Stock | 60,000 | 60,000 | D |
Explanation of responses
- F1The option is scheduled to vest in six semi-annual installments over the three-year period following the grant date, subject to the reporting person's continued employment or service with the issuer through the applicable vesting date.